Home Cart Sign in  
Chemical Structure| 681492-22-8 Chemical Structure| 681492-22-8

Structure of Delamanid
CAS No.: 681492-22-8

Chemical Structure| 681492-22-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Delamanid, a mycobacterial cell wall synthesis inhibitor, inhibits the synthesisi of mucolic acids, cruciala component of the cell wall of the Mycobacterium tuberculosis complex.

Synonyms: OPC-67683

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Delamanid

CAS No. :681492-22-8
Formula : C25H25F3N4O6
M.W : 534.48
SMILES Code : FC(F)(F)OC1=CC=C(OC2CCN(C3=CC=C(OC[C@@]4(C)CN5C(O4)=NC([N+]([O-])=O)=C5)C=C3)CC2)C=C1
Synonyms :
OPC-67683
MDL No. :MFCD18251539
InChI Key :XDAOLTSRNUSPPH-XMMPIXPASA-N
Pubchem ID :6480466

Safety of Delamanid

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
THP-1 cells 0.3 mg/mL 0-24 hours DLM significantly suppressed CXCL10 expression, which majorly depended on inhibiting the JAK/STAT pathway, and impaired the migration of PBMCs. Front Immunol. 2022 Nov 8;13:923492.
U937 cells 0.3 mg/mL 0-24 hours DLM significantly suppressed CXCL10 expression, which majorly depended on inhibiting the JAK/STAT pathway, and impaired the migration of PBMCs. Front Immunol. 2022 Nov 8;13:923492.
Human hepatocytes 10 μg/ml 1 or 24 hours Detection of covalent binding of DLM metabolites with NAD derivatives Antimicrob Agents Chemother. 2020 Apr 21;64(5):e01755-19.
Mycobacterium tuberculosis var. Bacille de Calmette et Guérin (BCG) 10 μg/ml 1 or 24 hours Detection of covalent binding of DLM metabolites with NAD derivatives Antimicrob Agents Chemother. 2020 Apr 21;64(5):e01755-19.
Mycobacterium bovis BCG Tokyo 0.016, 0.08, 0.4 mg/L 7 days To evaluate the bactericidal activity of delamanid against growing and dormant bacilli. Delamanid showed significant bactericidal activity under both aerobic and anaerobic conditions. Antimicrob Agents Chemother. 2017 May 24;61(6):e02402-16.
Mycobacterium kansasii 0.25 μg/mL (MIC50) Evaluate the in vitro activity of Delamanid against nontuberculous mycobacteria, results showed MIC50 value of 0.25 μg/ml for M. kansasii Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00665-19.
Mycobacterium abscessus subsp. massiliense >16 μg/mL (MIC50) Evaluate the in vitro activity of Delamanid against nontuberculous mycobacteria, results showed MIC50 value of >16 μg/ml for M. abscessus subsp. massiliense Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00665-19.
Mycobacterium abscessus subsp. abscessus >16 μg/mL (MIC50) Evaluate the in vitro activity of Delamanid against nontuberculous mycobacteria, results showed MIC50 value of >16 μg/ml for M. abscessus subsp. abscessus Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00665-19.
Mycobacterium intracellulare 16 μg/mL (MIC50) Evaluate the in vitro activity of Delamanid against nontuberculous mycobacteria, results showed MIC50 value of 16 μg/ml for M. intracellulare Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00665-19.
Mycobacterium avium 8 μg/mL (MIC50) Evaluate the in vitro activity of Delamanid against nontuberculous mycobacteria, results showed MIC50 value of 8 μg/ml for M. avium Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00665-19.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Chronic tuberculosis model Oral 100 mg Twice daily for 7 days To determine the PK/PD breakpoint for Delamanid, results showed that at an MIC of 0.016 mg/L, the probability of target attainment was 100%. Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0140122
Guinea pig Chronic TB infection model Oral 100 mg/kg Once daily for 4 or 8 weeks To evaluate the bactericidal activity of delamanid in a guinea pig TB model. Delamanid demonstrated strong bactericidal activity after 4 or 8 weeks of treatment, particularly within hypoxic lesions of the lung. Antimicrob Agents Chemother. 2017 May 24;61(6):e02402-16.
BALB/c mice Tuberculosis-infected Mice model Oral 2.5 mg/kg 5 times per week for 24 weeks To evaluate the efficacy of the BDL regimen in a tuberculosis-infected Mice model, results showed that the BDL regimen was more effective than the standard HRZE regimen. J Infect Dis. 2021 Sep 17;224(6):1039-1047
BALB/c and C3HeB/FeJ mice Tuberculosis model Gavage D2.5 Once daily, 5 days per week To evaluate the bactericidal and sterilizing activity of Delamanid in combination with Bedaquiline, Pyrazinamide, and Moxifloxacin. Results showed that BZMD and BZOD regimens exhibited sterilizing activity similar to PZM in BALB/c mice, and BZOD had efficacy similar to PZMH in C3HeB/FeJ mice. Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0239821

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT04421495 Multidrug Resistant Tuberculos... More >>is Less << PHASE4 UNKNOWN 2024-07-16 Beijing Chest Hospital, Capita... More >>l Medical University, Beijing, 101149, China|Changsha Central Hospital, Changsha, China|Public Health Clinical Center of Chengdu, Chengdu, China|Chongqing Infectious Disease Medical Center, Chongqing, China|Fuzhou Pulmonary Hospital of Fujian, Fuzhou, China|Guangzhou Chest Hospital, Guangzhou, China|Guiyang Public Health Clinical Center, Guiyang, China|Heilongjiang Province center for tuberculosis Control and Prevention, Haerbin, China|Hangzhou Red Cross Hospital, Hangzhou, China|Jiamusi Tumor Hospital, Jiamusi, China|Tuberculosis Hospital in Jilin Province, Jilin, China|Shandong Provincial Chest Hospital, Jinan, China|The Third People's Hospital of Kunming City, Kunming, China|Lanzhou Pulmonary Hospital, Lanzhou, China|Longtan Hospital of Guangxi Zhuang Autonomous Region, Liuzhou, China|Jiangxi Chest (Third People) Hospital, Nanchang, China|Shanghai Pulmonary Hospital, Shanghai, China|Hebei Chest Hospital, Shijiangzhuang, China|The Fifth People Hospital of Suzhou, Suzhou, China|The Fourth People's Hospital of Taiyuan, Taiyuan, China|Wuhan Institute For Tuberculosis Control, Wuhan, China|Wuhan Jinyintan Hospital, Wuhan, China|Xi'an Chest Hospital, Xi'an, China|Shanxi Provincial Tuberculosis Institute, Xian, China|Henan Provincial Chest Hospital, Zhengzhou, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.87mL

0.37mL

0.19mL

9.35mL

1.87mL

0.94mL

18.71mL

3.74mL

1.87mL

References

 

Historical Records

Categories